Results 131 to 140 of about 1,630,140 (194)

Category IV indications for therapeutic apheresis: ASFA fourth special issue

open access: yes, 2010
The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned
Shaz, Beth H.   +10 more
core   +1 more source

An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres

open access: yesMedical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs   +15 more
wiley   +1 more source

[The Italian Registry for Therapeutic Apheresis: fifteen years of activity]

open access: yes, 2009
There is currently no consensus about the indications for therapeutic apheresis, also due to the lack of large clinical trials. A registry where all the data can be organized and analyzed therefore becomes a priority for all professionals involved in ...
Aureli, Fabio, Ferraro, Pietro Manuel
core   +1 more source

A Critical Comparative Analysis of Immunoadsorption and Conventional Plasma Exchange in Preconditioning of ABO-incompatible Renal Transplant Cases

open access: yesIndian Journal of Transplantation
ABO-incompatible renal transplants often require expensive pre-transplant conditioning using therapeutic apheresis (TA) procedures to reduce the titers of isoagglutinins in the recipients, which may have adverse effects on the graft acceptance and ...
Prashant Pandey   +6 more
doaj   +1 more source

Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax

open access: yesThe FASEB Journal, Volume 40, Issue 19, 15 October 2026.
Venetoclax‐induced Bcl‐2 inhibition corresponds with Mcl‐1 attenuation and decrease of Nucleolin (NCL) level and activity in sensitive cells. Simultaneously, distinct cell subpopulations with opposite mitochondrial (CellROX label, magenta) and cellular (H2DCFDA stain, green) ROS occur, and the H2DCFDA‐positive population shows markers of early ...
Kateřina Wolfová   +2 more
wiley   +1 more source

Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis. [PDF]

open access: yesTransfus Med Hemother, 2021
Stegmayr B   +39 more
europepmc   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

open access: yes
Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco   +4 more
wiley   +1 more source

A loxoscelism case received therapeutic apheresis and hyperbaric oxygen therapy. [PDF]

open access: yesSaudi Med J, 2020
Cetinkaya A   +3 more
europepmc   +1 more source

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy. [PDF]

open access: yesTransfus Apher Sci, 2020
Colpo A   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy